Company intelligence / Profile preview

BioPharma Secured Investments III

Cayman Islands

Ownership: Private
Development stage: Other

Overview

BioPharma Secured Investments III is a Cayman-domiciled private equity fund overseen and raised by Pharmakon Advisors LP, designed to invest in credit and structured transactions within the life sciences, biotechnology, and pharmaceutical industries, often supporting late-stage or commercial-stage companies through debt or royalty financing. No direct clinical results are generated by the fund itself.

Industry: Investors

Partnerships

Custodian: Bank of AmericaAuditor: Ernst & Young LLPMarketers: Groton Partners LLCMarketers: 2M Management LLCMarketers: VIER Kleeblatt Investment AG

Beyond the preview

Go deeper on BioPharma Secured Investments III.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on BioPharma Secured Investments III.

Explore the full profile